| 1. |
Determining the worth of costly colorectal cancer treatment |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
COX-2s confer QOL benefit in clinical practice in Latin America |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 3-4
L Everitt,
Preview
|
|
摘要:
Randomised, controlled clinical trials have shown that Merck & Co's selective cyclo-oxygenase-2 (COX-2) inhibitors etoricoxib and rofecoxib are at least as effective as conventional non-selective NSAIDs as analgesic and anti-inflammatory agents. Researchers from North and South America set out to evaluate the effect of both agents on QOL and pain among patients treated in clinical practice for chronic low back pain or osteoarthritis in Latin American countries, and presented their results at the Annual European Congress of Rheumatology [Berlin, Germany; June 2004].1,2They found that improvements in pain and QOL were significantly greater following treatment with the COX-2 inhibitors compared with conventional NSAIDs.
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
New guidelines for MTCT of HIV infections published by WHO |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
S African decision to end nevirapine monotherapy condemned |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Oseltamivir warranted for influenza among paediatric individuals? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Contraception unequivocally cost effective in the US |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Fondaparinux for DVT prevention: benefits at extra cost |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Indirect costs account for majority of migraine cost burden in Spain |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Total vancomycin costs assessed in MRSA infections |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to sell its antiretroviral agent lamivudine [Epivir] at preferential prices until 2006 in China, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 458,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
